Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

New discovery could lead to faster and more effective treatments for chronic health complications

A world-first discovery by researchers at Monash University and The University of Queensland could lead to faster and more effective treatments for chronic health complications, such as cardiovascular disease and cancer, with 'fluorescent' in vivo biosensors.

26 Jan 2021

Researchers engineer antibody that broadly neutralizes a range of clade 1 sarbecoviruses

Researchers have engineered an antibody that neutralizes SARS-CoV-2 with a potency that "rivals" current lead SARS-CoV-2 clinical neutralizing antibodies, and that also broadly neutralizes a range of clade 1 sarbecoviruses.

26 Jan 2021

New SARS-CoV-2 variant must be curbed to protect UK health services, warn experts

A new research project called REACT-1 – launched by researchers at the Imperial College London, Imperial College Healthcare NHS Trust, and Ipsos MORI – has aimed to better understand the dynamics of SARS-CoV-2’s viral spread across the UK.

26 Jan 2021

Recombinant SARS-CoV-2 protein vaccine less immunogenic but more antigenic than expected

Now, a new preprint research paper posted to the medRxiv server presents preliminary results of a stabilized SARS-CoV-2 pre-fusion spike protein vaccine expressed in a baculovirus system (CoV2 preS dTM), with two different adjuvant formulations.

26 Jan 2021

Circulating antiphospholipid antibodies drive endothelial cell activation in COVID-19

With the emergence of COVID-19 (coronavirus disease 2019), researchers have been closely investigating the complex interplay between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the human immune system, and COVID-19 disease severity.

25 Jan 2021

Probiotics as adjuvant therapy for COVID-19 patients

In a recent review published in the Journal of Diabetes & Metabolic Syndrome: Clinical Research & Reviews, Luigi Santacroce and Francesco Inchingolo et al. address the many factors such as dysbiosis (imbalance in the microbiota) that could influence the SARS-CoV-2 infection course.

25 Jan 2021

New SARS-CoV-2 variants resistant to convalescent sera and and monoclonal antibodies

Researchers studying the effect of convalescent sera and monoclonal antibodies from recovered patients found the UK and South African SARS-CoV-2 variants are more resistant to neutralization compared to the wild-type virus.

25 Jan 2021

New drug screening platform identifies inhibitors of SARS-CoV-2

Researchers in the UK and the United States have developed a stem-cell-based screening platform for identifying compounds that inhibit infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative agent for coronavirus disease 2019 (COVID-19).

25 Jan 2021

Bispecific antibody shows efficacy against new SARS-CoV-2 variants

A team of international scientists has recently developed a bispecific antibody that can bind two non-overlapping regions of the spike receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and completely prevent the viral-host interaction.

25 Jan 2021

Combining anti-tumor antibodies with standard-of-care improves therapeutic outcomes in cancer

The cover for issue 2 of Oncotarget features Figure 4, "Combination therapy TA99/ICB reduced the lung tumor burden in the B16 model of metastases," published in "Improved therapeutic efficacy of unmodified anti-tumor antibodies by immune checkpoint blockade and kinase targeted therapy in mouse models of melanoma" by Pérez-Lorenzo, et al. which reported that here, the authors showed that removing immune suppression and enhancing stimulatory signals increased the anti-tumor activity of unmodified TA99 antibodies with a significant reduction of growth of solid tumors and lung metastases in mouse models of melanoma.

25 Jan 2021

Promising nanobodies against COVID-19 produced by llamas

News-Medical speaks to Dr. David Brody about his latest research that involved discovering nanobodies produced by llamas that could help combat coronavirus.

25 Jan 2021

Second-generation double antibody protects from SARS-CoV-2 and its tested variants

The Institute for Research in Biomedicine (IRB; Bellinzona, Switzerland), affiliated to the Università della Svizzera italiana (USI) developed a second-generation 'double antibody' that protects from SARS-CoV-2, the virus causing COVID-19, and all its tested variants. It also prevents the virus from mutating to resist the therapy.

24 Jan 2021

Transcriptional regulator BRD2 as a potential therapeutic target for COVID-19

A team of international scientists has demonstrated that therapeutic inhibition of a transcriptional regulator BRD2, required for the endogenous expression of angiotensin-converting enzyme 2 (ACE2), can potentially suppress severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The study is currently available on the bioRxiv* preprint server.

24 Jan 2021

Researchers identify protein that may represent a safer treatment target for pancreatic cancer

Researchers from Queen Mary University of London, have identified a protein that may represent a novel therapeutic target for the treatment of pancreatic cancer.

22 Jan 2021

NSAIDs dampen antibody and inflammatory responses to SARS-CoV-2 infection in mice

New research shows that non-steroidal anti-inflammatory drugs (NSAIDs) reduced both antibody and inflammatory responses to SARS-CoV-2 infection in mice. The study appears this week in the Journal of Virology, a publication of the American Society for Microbiology.

22 Jan 2021

Antibody News and Research

Further Reading

New discovery could lead to faster and more effective treatments for chronic health complications

Researchers engineer antibody that broadly neutralizes a range of clade 1 sarbecoviruses

New SARS-CoV-2 variant must be curbed to protect UK health services, warn experts

Recombinant SARS-CoV-2 protein vaccine less immunogenic but more antigenic than expected

Circulating antiphospholipid antibodies drive endothelial cell activation in COVID-19

Probiotics as adjuvant therapy for COVID-19 patients

New SARS-CoV-2 variants resistant to convalescent sera and and monoclonal antibodies

New drug screening platform identifies inhibitors of SARS-CoV-2

Bispecific antibody shows efficacy against new SARS-CoV-2 variants

Combining anti-tumor antibodies with standard-of-care improves therapeutic outcomes in cancer

Promising nanobodies against COVID-19 produced by llamas

Second-generation double antibody protects from SARS-CoV-2 and its tested variants

Transcriptional regulator BRD2 as a potential therapeutic target for COVID-19

Researchers identify protein that may represent a safer treatment target for pancreatic cancer

NSAIDs dampen antibody and inflammatory responses to SARS-CoV-2 infection in mice

Novel neutralizing antibodies targeting SARS-CoV-2 N-terminal domain discovered

Study identifies a host of agents with anti-SARS-CoV-2 potential

Accurate quantitative COVID-19 antibody test kit by EKF

EKF opens larger facility to increase production of key component for COVID-19 testing regime

Infusion of convalescent blood plasma benefits patient with severe COVID-19

How to make hybridoma-based antibody discovery more efficient eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo